Oncotarget

Clinical Research Papers:

Improved glycemic control with proximal intestinal bypass and weight loss following gastrectomy in non-obese diabetic gastric cancer patients

Ali Guner, Minah Cho, Taeil Son, Hyoung-Il Kim, Sung Hoon Noh and Woo Jin Hyung _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:104605-104614. https://doi.org/10.18632/oncotarget.22262

Metrics: PDF 1182 views  |   HTML 2171 views  |   ?  


Abstract

Ali Guner1,2, Minah Cho1,3, Taeil Son1,3, Hyoung-Il Kim1,3, Sung Hoon Noh1,3 and Woo Jin Hyung1,3

1Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea

2Department of General Surgery, Karadeniz Technical University College of Medicine, Farabi Hospital, Trabzon, Turkey

3Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea

Correspondence to:

Woo Jin Hyung, email: [email protected]

Keywords: gastric cancer, gastrectomy, diabetes, proximal intestinal bypass, weight loss

Abbreviations: BMI: Body mass index, DM: Diabetes mellitus, HbA1c: Glycosylated hemoglobin

Received: June 24, 2017     Accepted: September 23, 2017     Published: November 01, 2017

ABSTRACT

Purpose: The aim of this study was to assess whether gastrectomy influences glycemic control in non-obese diabetic gastric cancer patients and to identify factors related to glucose metabolism after gastrectomy.

Materials and Methods: We retrospectively analyzed changes in glucose metabolism in 238 non-obese (body mass index < 30 kg/m2) patients with type II diabetes who underwent distal gastrectomy with either gastroduodenostomy (n = 91) or gastrojejunostomy (n = 147) for stage I gastric cancer. We collected demographics, diabetes-related features, surgery-related features, and changes in glucose metabolism during follow-up. The effect of surgery on the course of diabetes was evaluated at different time points according to fasting blood glucose levels and use of diabetes-related medication.

Results: Preoperatively, the mean body mass index was 24.3 ± 2.3. Weight, body mass index and fasting blood glucose of all patients were significantly lower compared to preoperative levels at all time points. Weight loss after 6 months and the percentage of patients whose weight loss ratio was higher than 10% after one year were greater in the gastrojejunostomy group than the gastroduodenostomy group. Overall, 88 (37%) patients showed improvement in their diabetes course at one month after surgery; 152 (64%) showed improvement after 2 years. Duration of diabetes, weight loss, and reconstruction type were associated with improvement in diabetes at different time points. At 6 months and thereafter, the percentage of patients with an improved diabetes course was highest in the gastrojejunostomy plus higher than 10% weight loss group.

Conclusions: Although weight loss may be associated with adverse effects of gastrectomy, postoperative weight loss in an acceptable range is a useful measure of the better glycemic control for the group of diabetic patients. Selecting gastrojejunostomy during gastrectomy and inducing acceptable weight loss after gastrectomy could be beneficial to the non-obese diabetic gastric cancer patients for improved glycemic control.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22262